t
On January 13, 2026, the Bangladesh Securities and Exchange Commission (BSEC) informed Beximco Pharmaceuticals PLC that it would not approve the Company's requests, made in April, October, and November 2025, for extensions to submit and publish its Q3 2025, Annual Results to 30 June 2025, and Q1 2025 financial results. The BSEC subsequently issued an Order on January 15, 2026, requiring Beximco to hold a Board meeting within 12 days, including nine proposed additional independent directors. In response, Beximco filed a Writ Petition in the High Court of Bangladesh, which issued a Rule requiring BSEC to show cause and directed the matter to be heard with Writ Petition No. 525 of 2025.
| Date | 28 Jan 2026 |
| Time | 14:01:18 |
| Category | Miscellaneous |
| ID | 7767Q |
28 January 2026
BEXIMCO PHARMACEUTICALS PLC.
Further Order re Request of Extension to Publish the Company's Financial Results for 2025
Beximco Pharmaceuticals PLC. ("the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces further developments with regards to the publication of its financial results for 2025.
The Company received correspondence on 13 January 2026 from the Bangladesh Securities and Exchange Commission (BSEC) informing the Company that it is not in a position to approve the Company's application for extensions to submit and publish its Q3 2025 financial results, Annual Results to 30 June 2025, and its first quarter financial results ended 30 September 2025. These requests were previously made by the Company in April, October and November 2025. This was followed by an Order from BSEC dated 15 January 2026, requiring the Company to hold a meeting of the Board of Directors (including the BSEC's proposed nine additional independent directors) within 12 days from the date of the Order.
In response, the Company filed a Writ Petition in the High Court Division of the Supreme Court of Bangladesh challenging the Order dated 15 January 2026. At a hearing, the High Court Division issued a Rule requiring BSEC to show cause as to why this Order should not be declared to have been made without any lawful authority. The Court also directed that this matter should be heard along with Writ Petition No. 525 of 2025 relating to the BSEC's proposed appointment of an additional nine independent non-executive directors to the Company's Board of Directors (BSEC Order). Further to the announcement on 19 December 2025, a High Court Bench has now been fixed for hearing of the Writ Petition.
The Company will continue to make announcements regarding any developments that need to be disclosed in accordance with its obligations under the AIM Rules, whilst the temporary suspension is in place.
Shares continue to trade on the Dhaka Stock Exchange and the Chittagong Stock Exchange.
For further information please visit www.beximcopharma.com or enquire to:
|
Beximco Pharma |
|
Mohammad Ali Nawaz, Chief Financial Officer Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS Executive Director & Company Secretary Tel: +880 2 41060531, Ext. 10140
|
|
SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555
|
|
SP Angel Corporate Finance LLP (Broker) Matthew Johnson Tel: +44 (0) 20 3470 0470
|
|
FTI Consulting Simon Conway / Sam Purewal Tel: +44 (0)20 3727 1000
|
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.